title: Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer.
abstract: OBJECTIVE
  To evaluate the effect of adjuvant chemoradiotherapy (CRT) on locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) for patients with extrahepatic biliary tract cancer treated with curative resection.
  
  
  METHODS
  The study involved 168 patients with extrahepatic biliary tract cancer undergoing curative resection between August 2001 and April 2009. Of the 168 patients, 115 received adjuvant CRT (CRT group) and 53 did not (no-CRT group). Gender, age, tumor size, histologic differentiation, pre- and postoperative carbohydrate antigen 19-9 level, resection margin, vascular invasion, perineural invasion, T stage, N stage, overall stage, and the use of adjuvant CRT were analyzed to identify the prognostic factors associated with LRC, DFS, and OS.
  
  
  RESULTS
  For all patients, the 5-year LRC, DFS, and OS rate was 54.8%, 30.6%, and 33.9%, respectively. On univariate analysis, the 5-year LRC, DFS, and OS rates in the CRT group were significantly better than those in the no-CRT group (58.5% vs. 44.4%, p=.007; 32.1% vs. 26.1%, p=.041; 36.5% vs. 28.2%, p=.049, respectively). Multivariate analysis revealed that adjuvant CRT was a significant independent prognostic factor for LRC, DFS, and OS (p<.05).
  
  
  CONCLUSIONS
  Our results have suggested that adjuvant CRT helps achieve LRC and, consequently, improves DFS and OS in patients with extrahepatic biliary tract cancer.
authors.affiliation: Center for Liver Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
authors.forename: Tae Hyun
authors.initials: TH
authors.lastname: Kim
authors.forename: Sung-Sik
authors.initials: SS
authors.lastname: Han
authors.forename: Sang-Jae
authors.initials: SJ
authors.lastname: Park
authors.forename: Woo Jin
authors.initials: WJ
authors.lastname: Lee
authors.forename: Sang Myung
authors.initials: SM
authors.lastname: Woo
authors.forename: Sung Ho
authors.initials: SH
authors.lastname: Moon
authors.forename: Tae
authors.initials: T
authors.lastname: Yoo
authors.forename: Sang Soo
authors.initials: SS
authors.lastname: Kim
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Eun Kyung
authors.initials: EK
authors.lastname: Hong
authors.forename: Dae Yong
authors.initials: DY
authors.lastname: Kim
authors.forename: Joong-Won
authors.initials: JW
authors.lastname: Park
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D017734:Bile Ducts, Extrahepatic / Q000473:pathology / Q000601:surgery; D018395:CA-19-9 Antigen / Q000097:blood; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011832:Radiation Injuries / Q000150:complications; D012189:Retrospective Studies; D012737:Sex Factors; D047368:Tumor Burden
chemical_list: D018395:CA-19-9 Antigen